NASDAQ: ORIC

Oric Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

The consensus among 3 Wall Street analysts covering (NASDAQ: ORIC) stock is to Buy ORIC stock.

Out of 3 analysts, 0 (0%) are recommending ORIC as a Strong Buy, 3 (100%) are recommending ORIC as a Buy, 0 (0%) are recommending ORIC as a Hold, 0 (0%) are recommending ORIC as a Sell, and 0 (0%) are recommending ORIC as a Strong Sell.

If you're new to stock investing, here's how to buy Oric Pharmaceuticals stock.

(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.

Oric Pharmaceuticals's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast ORIC's revenue for 2026 to be $1,085,570,671, with the lowest ORIC revenue forecast at $86,191,038, and the highest ORIC revenue forecast at $2,084,950,304. On average, 2 Wall Street analysts forecast ORIC's revenue for 2027 to be $4,506,209,310, with the lowest ORIC revenue forecast at $20,729,490, and the highest ORIC revenue forecast at $8,991,689,131.

In 2028, ORIC is forecast to generate $23,822,002,830 in revenue, with the lowest revenue forecast at $23,822,002,830 and the highest revenue forecast at $23,822,002,830.

According to 3 Wall Street analysts that have issued a 1 year ORIC price target, the average ORIC price target is $19.00, with the highest ORIC stock price forecast at $27.00 and the lowest ORIC stock price forecast at $14.00.

On average, Wall Street analysts predict that Oric Pharmaceuticals's share price could reach $19.00 by Oct 26, 2024. The average Oric Pharmaceuticals stock price prediction forecasts a potential upside of 101.48% from the current ORIC share price of $9.43.

(NASDAQ: ORIC) forecast ROE is N/A, which is considered weak.